Navigation Links
Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
Date:11/4/2010

rval of –0.60 g/dL in both populations, greater than the pre-defined non-inferiority margin of –1.0 g/dL. These results indicate that the primary endpoint was met. Both the VPRIV and imiglucerase groups showed substantial improvements in the secondary endpoints, including platelet counts, spleen volume, liver volume, and plasma biomarkers with no statistically significant difference demonstrated between the treatment groups. The majority of adverse events were mild or moderate in severity, including one serious adverse event (SAE) seen with VPRIV which was an allergic skin reaction that resolved without sequalae.

Shire also reported important findings that suggested substantial antigenic differences when antibody response to treatment with VPRIV and imiglucerase were compared. No patient treated with VPRIV developed anti-drug antibodies while 4 patients in the imiglucerase group developed antibodies to imiglucerase. Of these four imiglucerase treated patients, 1 patient had antibodies that inhibited enzyme activity in vitro and enzyme uptake in a cell-based assay. 3 patients had antibodies that did not inhibit enzyme activity or uptake.

Data from the Phase III clinical trial extension were also presented at ASHG. In the six month extension study patients from study 034 with type 1 Gaucher disease previously treated with imiglucerase, successfully transitioned to VPRIV and maintained hematological parameters at therapeutic levels through 18 months of continuous treatment. VPRIV was generally well tolerated, and appeared to show a favourable immunogenicity profile.

"For physicians, drug safety is a major consideration; the reported lack of antibodies to infused velaglucerase alfa in these studies, both in naive and switch patients, is re-assuring to patients and their physicians alike," said Gregory M. Pastores MD, Associate Professor of Neurology and Pediatrics at the NYU School of Medicine in New York.

Shire's VPRIV clinical t
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
(Date:9/19/2014)... -- According to market research report, ... & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, ... Geography - Global Trends & Forecast to 2019", ... market on the basis of various types, applications, ... market size of each of these segments in ...
(Date:9/19/2014)... and ORLANDO, Fla. , ... supporting Inspire therapy continues to grow, with the publication ... published on-line in Otolaryngology – Head and ... causes a worsening of both objective and subjective measures ... directly attribute Inspire therapy for the reduction in obstructive ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
(Date:9/21/2014)... UNIWIGS, one of the leading online stores ... pieces, offers a line of human hair lace wigs inspired ... also shows people what the latest celebrity hairstyles ... there are 4 different hairstyles to choose from: a style ... lace wigs and a hot ombre red lace wig. People ...
(Date:9/21/2014)... More than a quarter of house fires are ... of two ways. The first type of dryer fire occurs ... type of dryer fire occurs when lint builds up in the ... due to malfunctioning electrical systems so if it doesn’t appear to ... Here are some ways that you can prevent dryer fires. , ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Expert witness ... released the findings from its 2014 Expert Witness Fees ... increasingly complex, the demand and compensation for qualified and ... in the Survey’s 16-year history. , The nearly ... hour for their expert work, an increase of 3.2% ...
(Date:9/21/2014)... "I wanted to be able to ... sugary, foul-tasting energy drinks," said an inventor from Fresh ... to drink plain, old coffee. That is why I ... developed ENERG CHEWING GUM to provide a healthy energy ... formula contains nutritious vitamins, minerals and antioxidants. It also ...
(Date:9/21/2014)... "I want to help people who are having ... money for chiropractors," said an inventor from St. Amat, ... for myself." , The Stretch is a device that ... and align the spine properly. It improves flexibility and ... nerves. Compact and easy to use, it's ideal for ...
Breaking Medicine News(10 mins):Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2
... of deadly neuroectodermal tumors , MONDAY, Dec. 7 (HealthDay ... role in a particularly aggressive type of childhood brain ... tumors (CNS-PNETs), the discovery of these oncogenes may lead ... , "Lack of insight into the molecular pathogenesis of ...
... , , SAN FRANCISCO, Dec. 7 Senior advocacy organizations ... grant from Verizon on Tuesday (Dec. 8) to continue the Commitment to End Abuse ... Hank Lacayo, president and CEO, Congress of California Seniors, ... and CEO, Self-Help for the Elderly, ...
... , GREENDALE, Wis., Dec. 7 Taste of Home ... Comfort Food Diet Cookbook, featuring America,s favorite comfort recipes with ... Food Diet Cookbook , on shelves December 31, 2009, is a ... pounds without feeling deprived. Enjoy pizza, lasagna, mac-n-cheese, pulled pork and ...
... ― The second-generation proteasome inhibitor carfilzomib is showing noteworthy ... among multiple myeloma patients in a phase II clinical ... of the American Society of Hematology. The updated ... relapsed or resistant multiple myeloma who have received one ...
... ... dental emergency, finding a qualified, experienced dentist is a crucial step in preserving your smile ... Minneapolis, ... stand against the high prices and inconvenience of emergency dental procedures. Whether a tooth is ...
... fewer hassles, study finds , MONDAY, Dec. 7 (HealthDay News) ... just as effective in preventing dangerous venous clots as an ... to manage, a new study finds. , Dabigatran is marketed ... not yet approved for use in the United States. , ...
Cached Medicine News:Health News:New Target May Be Eyed in Kids' Brain Cancer 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 3Health News:Drug shows positive responses, low side-effects in multiple myeloma 2Health News:Minneapolis Dentists, Shamblott Family Dentistry, Ease the Pain and Cost of Emergency Dental Procedures 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
Medicine Products: